Dopamine Hydrochloride shortage — US supply status & alternatives

Dopamine Hydrochloride

ATC C01CA04

🇦🇺 AUST R 332320 · Juno Pharmaceuticals Pty Ltd

In supply · Australia

Dopamine Hydrochloride In Dextrose

In supply · 🇦🇺 Australia · short in🇺🇸 US🇨🇦 CA🇫🇷 FR

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)

Brand names	Dopamine Hydrochloride In Dextrose

ATC level 5	C01CA04

ATC level 4	C01CA

Therapeutic category	Auto-created by U.S. Food and Drug Administration — Drug Shortages scraper

Controlled substance	No

Marketing-authorisation holders	Juno Pharmaceuticals Pty Ltd, MERCURY PHARMACEUTICALS LIMITED, S.A.L.F. SPA LABORATORIO FARMACOLOGICO, HIKMA PHARMACEUTICALS USA INC. +4 more

Registrations on file	12

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

1 API manufacturer

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Very high concentration risk

Siegfried Pharmachemikalien Minden GMBH

Manufacturing countries: Germany · Source: FDA List of Drug Master Files

Recalls official enforcement reports

🇺🇸

Dopamine Hci Active Pharmaceutical Ingredient Packaged In Va

Attix Pharmaceuticals · Nov 2014

Class IIdetails ↗

🇺🇸

DOPAMINE HYDROCHLORIDE AND DEXTROSE

Baxter Healthcare Corp. · Sept 2014

Class IIdetails ↗

Verified timeline regulator events

🇫🇷 27 Apr 2026

Shortage resolved

🇫🇷 14 Nov 2025

medium reported

🇺🇸 27 Aug 2025

critical reported

🇺🇸 27 Aug 2025

critical reported

🇺🇸 6 Nov 2017

critical reported

🇺🇸 6 Nov 2017

critical reported

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders12 registrations · 8 MA holders

Product	Strength	Form	Market	MA holder	Status
DOPAMINE JUNO dopamine hydrochloride	200 mg	—	🇦🇺 AU	Juno Pharmaceuticals Pty Ltd	Active
DOPAMINE HYDROCHLORIDE 40MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION	40MG	solution	🇬🇧 GB	MERCURY PHARMACEUTICALS LIMITED	Active
DOPAMINE HYDROCHLORIDE 40 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION	40 MG	solution	🇬🇧 GB	S.A.L.F. SPA LABORATORIO FARMACOLOGICO	Active
Dopamine Hydrochloride	40mg/mL	injection	🇺🇸 US	HIKMA PHARMACEUTICALS USA INC.	Active
Dopamine Hydrochloride	80mg/mL	injection	🇺🇸 US	HIKMA PHARMACEUTICALS USA INC.	Active
Dopamine Hydrochloride and Dextrose	80mg/100mL	injection	🇺🇸 US	BAXTER HEALTHCARE CORPORATION	Active
Dopamine Hydrochloride and Dextrose	160mg/100mL	injection	🇺🇸 US	BAXTER HEALTHCARE CORPORATION	Active
Dopamine Hydrochloride and Dextrose	320mg/100mL	injection	🇺🇸 US	BAXTER HEALTHCARE CORPORATION	Active
Dopamine Hydrochloride in Dextrose	1.6mg/mL	injection	🇺🇸 US	Hospira, Inc.	Active
Dopamine Hydrochloride in Dextrose	3.2mg/mL	injection	🇺🇸 US	Hospira, Inc.	Active
DOPAMINE HYDROCHLORIDE	1.6mg/mL	injection	🇺🇸 US	HF Acquisition Co LLC, DBA HealthFirst	Active
Dopamine Hydrochloride And 5% Dextrose Injection Usp	5%	solution	🇨🇦 CA	HOSPIRA HEALTHCARE ULC	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.